Suppr超能文献

早期急性呼吸窘迫综合征中分泌型磷脂酶 A2 介导的磷脂酰甘油耗竭。

Secretory phospholipase A2-mediated depletion of phosphatidylglycerol in early acute respiratory distress syndrome.

机构信息

Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

出版信息

Am J Med Sci. 2012 Jun;343(6):446-51. doi: 10.1097/MAJ.0b013e318239c96c.

Abstract

INTRODUCTION

Secretory phospholipases A2 (sPLA2) hydrolyze phospholipids in cell membranes and extracellular structures such as pulmonary surfactant. This study tests the hypothesis that sPLA2 are elevated in human lungs during acute respiratory distress syndrome (ARDS) and that sPLA2 levels are associated with surfactant injury by hydrolysis of surfactant phospholipids.

METHODS

Bronchoalveolar lavage (BAL) fluid was obtained from 18 patients with early ARDS (<72 hours) and compared with samples from 10 healthy volunteers. Secreted phospholipase A2 levels were measured (enzyme activity and enzyme immunoassay) in conjunction with ARDS subjects' surfactant abnormalities including surfactant phospholipid composition, large and small aggregates distribution and surface tension function.

RESULTS

BAL sPLA2 enzyme activity was markedly elevated in ARDS samples relative to healthy subjects when measured by ex vivo hydrolysis of both phosphatidylglycerol (PG) and phosphatidylcholine (PC). Enzyme immunoassay identified increased PLA2G2A protein in the ARDS BAL fluid, which was strongly correlated with the sPLA2 enzyme activity against PG. Of particular interest, the authors demonstrated an average depletion of 69% of the PG in the ARDS sample large aggregates relative to the normal controls. Furthermore, the sPLA2 enzyme activity against PG and PC ex vivo correlated with the BAL recovery of in vivo PG and PC, respectively, and also correlated with the altered distribution of the large and small surfactant aggregates.

CONCLUSIONS

These results support the hypothesis that sPLA2-mediated hydrolysis of surfactant phospholipid, especially PG by PLA2G2A, contributes to surfactant injury during early ARDS.

摘要

简介

分泌型磷脂酶 A2(sPLA2)可水解细胞膜和肺表面活性剂等细胞外结构中的磷脂。本研究旨在验证以下假说,即在急性呼吸窘迫综合征(ARDS)期间,sPLA2 在人肺中升高,并且 sPLA2 水平与通过水解表面活性剂磷脂导致的表面活性剂损伤有关。

方法

从 18 例早期 ARDS(<72 小时)患者的支气管肺泡灌洗液(BAL)中获得样本,并与 10 例健康志愿者的样本进行比较。联合测定 ARDS 患者的表面活性剂异常,包括表面活性剂磷脂组成、大、小聚集体分布和表面张力功能,来测量分泌型磷脂酶 A2 水平(酶活性和酶免疫测定)。

结果

与健康受试者相比,通过体外水解磷脂酰甘油(PG)和磷脂酰胆碱(PC),ARDS 样本中的 BAL sPLA2 酶活性明显升高。酶免疫测定确定 ARDS BAL 液中 PLA2G2A 蛋白增加,与 sPLA2 对 PG 的酶活性强烈相关。特别有趣的是,作者证明了 ARDS 样本中较大聚集体的 PG 平均耗竭了 69%,而正常对照则无此现象。此外,PG 和 PC 的 sPLA2 酶活性与 BAL 中 PG 和 PC 的体内回收率分别相关,并且与大、小表面活性剂聚集体的改变分布相关。

结论

这些结果支持以下假说,即 sPLA2 介导的表面活性剂磷脂水解,特别是 PLA2G2A 对 PG 的水解,导致早期 ARDS 中表面活性剂损伤。

相似文献

3
Surfactant protein B inhibits secretory phospholipase A2 hydrolysis of surfactant phospholipids.
Am J Physiol Lung Cell Mol Physiol. 2012 Jan 15;302(2):L257-65. doi: 10.1152/ajplung.00054.2011. Epub 2011 Oct 28.
4
Effect of cooling on lung secretory phospholipase A2 activity in vitro, ex vivo, and in vivo.
Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L498-L505. doi: 10.1152/ajplung.00201.2018. Epub 2019 Jan 3.
5
Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration.
Intensive Care Med. 2009 Feb;35(2):321-6. doi: 10.1007/s00134-008-1321-3. Epub 2008 Oct 14.
6
Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.
PLoS One. 2012;7(10):e47066. doi: 10.1371/journal.pone.0047066. Epub 2012 Oct 11.
7
Surfactant phospholipid changes after antigen challenge: a role for phosphatidylglycerol in dysfunction.
Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L610-7. doi: 10.1152/ajplung.00273.2004. Epub 2004 Sep 3.
8
Hydrolysis of surfactant-associated phosphatidylcholine by mammalian secretory phospholipases A2.
Am J Physiol. 1998 Oct;275(4):L740-7. doi: 10.1152/ajplung.1998.275.4.L740.
9
A role for phospholipase A2 in ARDS pathogenesis.
Mol Med Today. 1999 Jun;5(6):244-9. doi: 10.1016/s1357-4310(99)01470-7.
10
Secretory Phospholipase A Enzymes in Acute Lung Injury.
Cell Biochem Biophys. 2021 Sep;79(3):609-617. doi: 10.1007/s12013-021-01003-x. Epub 2021 Jun 8.

引用本文的文献

3
Fatal COVID-19 pulmonary disease involves ferroptosis.
Nat Commun. 2024 May 20;15(1):3816. doi: 10.1038/s41467-024-48055-0.
4
Effect of Surfactant Therapy on Clinical Outcomes of COVID-19 Patients With ARDS: A Systematic Review and Meta-Analysis.
Cureus. 2024 Mar 15;16(3):e56238. doi: 10.7759/cureus.56238. eCollection 2024 Mar.
6
Plasma lipid profile: a predictive marker of disease severity among COVID-19 patients-an opportunity for low-income countries.
Drugs Ther Perspect. 2022;38(6):286-291. doi: 10.1007/s40267-022-00916-8. Epub 2022 Jun 27.
7
An adverse outcome pathway for lung surfactant function inhibition leading to decreased lung function.
Curr Res Toxicol. 2021 May 27;2:225-236. doi: 10.1016/j.crtox.2021.05.005. eCollection 2021.
9
Secretory Phospholipase A Enzymes in Acute Lung Injury.
Cell Biochem Biophys. 2021 Sep;79(3):609-617. doi: 10.1007/s12013-021-01003-x. Epub 2021 Jun 8.

本文引用的文献

1
Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):320-5. doi: 10.1073/pnas.0909361107. Epub 2009 Dec 22.
2
Secreted phospholipases A(2): A proinflammatory connection between macrophages and mast cells in the human lung.
Immunobiology. 2009;214(9-10):811-21. doi: 10.1016/j.imbio.2009.06.006. Epub 2009 Jul 22.
3
Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia.
J Crit Care. 2010 Mar;25(1):176.e7-13. doi: 10.1016/j.jcrc.2009.05.002. Epub 2009 Jul 9.
5
Phospholipase A2 subclasses in acute respiratory distress syndrome.
Biochim Biophys Acta. 2009 Oct;1792(10):941-53. doi: 10.1016/j.bbadis.2009.06.007. Epub 2009 Jul 3.
6
7
Secretory group V phospholipase A2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice.
Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L879-87. doi: 10.1152/ajplung.90580.2008. Epub 2009 Mar 13.
8
Current perspectives in pulmonary surfactant--inhibition, enhancement and evaluation.
Biochim Biophys Acta. 2008 Oct;1778(10):1947-77. doi: 10.1016/j.bbamem.2008.03.021. Epub 2008 Apr 8.
9
Biochemistry and physiology of mammalian secreted phospholipases A2.
Annu Rev Biochem. 2008;77:495-520. doi: 10.1146/annurev.biochem.76.062405.154007.
10
Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness.
Am J Respir Crit Care Med. 2007 Dec 1;176(11):1072-8. doi: 10.1164/rccm.200707-1088OC. Epub 2007 Sep 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验